SynthesisThe oncologist2014
Sorafenib in metastatic thyroid cancer: a systematic review.
Synthesis in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2020Pooled it
- Pooled it
- Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report.Frontiers in oncology · 2026Article
- Familial Clinical Heterogeneity of Medullary Thyroid Cancer with GermlineJournal of clinical research in pediatric endocrinology · 2025Article
- Review
- Late Pancreatic Metastasis From Papillary Thyroid Carcinoma Diagnosed by Endoscopic Ultrasound-Guided Tissue Acquisition.Ochsner journal · 2025Article
- Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents.Cell communication and signaling : CCS · 2024Review
- Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature.World journal of clinical cases · 2023Article
- Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors.Indian journal of surgical oncology · 2022Article
- Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer.Thyroid research · 2022Article
- Ultrasound-guided implantation of radioactiveBMC cancer · 2021Article
- Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity.Oncotarget · 2021Article
- Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.Pharmaceutics · 2020Article
- Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.International journal of molecular sciences · 2020Review
- MOF Regulates TNK2 Transcription Expression to Promote Cell Proliferation in Thyroid Cancer.Frontiers in pharmacology · 2020Article
- Article
- DNA methylation alterations as therapeutic prospects in thyroid cancer.Journal of endocrinological investigation · 2019Review
- INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression.Cell & bioscience · 2018Article
- Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.BioMed research international · 2018Review
- Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
Corrections and comments
- Commented on byIn reply.2014
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSorafenib was recently approved by the U.S. Food and Drug Administration for radioiodine-resistant metastatic differentiated thyroid cancer (DTC). In addition, two drugs (vandetanib and cabozantinib) have received U.S. Food and Drug Administration approval for use in medullary thyroid cancer (MTC). Several published phase II trials have investigated the efficacy of sorafenib in thyroid cancers, but to date, results from those studies have not been compared.
methodsA systematic review of the literature was performed to assess response rate, median progression-free survival, and adverse events associated with sorafenib therapy for metastatic thyroid cancers.
resultsThis review included seven trials involving 219 patients: 159 with DTC (papillary, follicular, and poorly differentiated), 52 with MTC, and 8 with anaplastic thyroid cancer. No study reported complete responses to treatment. Overall partial response, stable disease, and progressive disease rates were 21%, 60%, and 20%, respectively. The median progression-free survival was 18 months for patients with all subtypes of thyroid cancer. Drug was discontinued in 16% of patients because of toxicities or intolerance, and the dose was reduced in a further 56%. Side effects with an incidence ≥ 50% were hand-foot syndrome (74%), diarrhea (70%), skin rash (67%), fatigue (61%), and weight loss (57%). Deaths not related to progressive disease occurred in nearly 4% of patients.
conclusionTreatment with sorafenib in patients with progressive DTC and MTC is a promising strategy, but the adverse event rate is high, leading to a high rate of dose reduction or discontinuation. Consequently, sorafenib use in patients with metastatic thyroid cancer requires careful selection of patients and careful management of side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.